Search tips
Search criteria 


Logo of transbThe Royal Society PublishingPhilosophical Transactions BAboutBrowse By SubjectAlertsFree Trial
Philos Trans R Soc Lond B Biol Sci. 2001 December 29; 356(1416): 1965–1973.
PMCID: PMC1088576

Plasmid-only rescue of influenza A virus vaccine candidates.


The potential threat of another influenza virus pandemic stimulates discussion on how to prepare for such an event. The most reasonable prophylactic approach appears to be the use of effective vaccines. Since influenza and other negative-stranded RNA viruses are amenable to genetic manipulation using transfection by plasmids, it is possible to outline new reverse genetics-based approaches for vaccination against influenza viruses. We suggest three approaches. First, we use a plasmid-only rescue system that allows the rapid generation of high-yield recombinant vaccine strains. Second, we propose developing second-generation live influenza virus vaccines by constructing an attenuated master strain with deletions in the NS1 protein, which acts as an interferon antagonist. Third, we suggest the use of Newcastle disease virus recombinants expressing influenza virus haemagglutinin proteins of pandemic (epizootic) strains as novel vaccine vectors for use in animals and possibly humans.

Full Text

The Full Text of this article is available as a PDF (207K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Basler CF, Reid AH, Dybing JK, Janczewski TA, Fanning TG, Zheng H, Salvatore M, Perdue ML, Swayne DE, García-Sastre A, et al. Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2746–2751. [PubMed]
  • Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000 Feb;136(2):168–175. [PubMed]
  • Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis. 2000 Mar;181(3):1133–1137. [PubMed]
  • Durbin JE, Fernandez-Sesma A, Lee CK, Rao TD, Frey AB, Moran TM, Vukmanovic S, García-Sastre A, Levy DE. Type I IFN modulates innate and specific antiviral immunity. J Immunol. 2000 Apr 15;164(8):4220–4228. [PubMed]
  • Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, García-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol. 1999 Nov;73(11):9679–9682. [PMC free article] [PubMed]
  • García-Sastre A. Negative-strand RNA viruses: applications to biotechnology. Trends Biotechnol. 1998 May;16(5):230–235. [PubMed]
  • García-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P, Muster T. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology. 1998 Dec 20;252(2):324–330. [PubMed]
  • García-Sastre A, Durbin RK, Zheng H, Palese P, Gertner R, Levy DE, Durbin JE. The role of interferon in influenza virus tissue tropism. J Virol. 1998 Nov;72(11):8550–8558. [PMC free article] [PubMed]
  • Hennet T, Ziltener HJ, Frei K, Peterhans E. A kinetic study of immune mediators in the lungs of mice infected with influenza A virus. J Immunol. 1992 Aug 1;149(3):932–939. [PubMed]
  • Hoffmann E, Neumann G, Hobom G, Webster RG, Kawaoka Y. "Ambisense" approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template. Virology. 2000 Feb 15;267(2):310–317. [PubMed]
  • Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108–6113. [PubMed]
  • Huang TS, Palese P, Krystal M. Determination of influenza virus proteins required for genome replication. J Virol. 1990 Nov;64(11):5669–5673. [PMC free article] [PubMed]
  • Maassab HF, Bryant ML. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol. 1999 Oct-Dec;9(4):237–244. [PubMed]
  • Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science. 1994 Jun 24;264(5167):1918–1921. [PubMed]
  • Neumann G, Zobel A, Hobom G. RNA polymerase I-mediated expression of influenza viral RNA molecules. Virology. 1994 Jul;202(1):477–479. [PubMed]
  • Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9345–9350. [PubMed]
  • Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991 Dec 15;108(2):193–199. [PubMed]
  • Palese P, Zheng H, Engelhardt OG, Pleschka S, García-Sastre A. Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11354–11358. [PubMed]
  • Pleschka S, Jaskunas R, Engelhardt OG, Zürcher T, Palese P, García-Sastre A. A plasmid-based reverse genetics system for influenza A virus. J Virol. 1996 Jun;70(6):4188–4192. [PMC free article] [PubMed]
  • Price GE, Gaszewska-Mastarlarz A, Moskophidis D. The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice. J Virol. 2000 May;74(9):3996–4003. [PMC free article] [PubMed]
  • Roberts A, Rose JK. Recovery of negative-strand RNA viruses from plasmid DNAs: a positive approach revitalizes a negative field. Virology. 1998 Jul 20;247(1):1–6. [PubMed]
  • Schirrmacher V, Ahlert T, Pröbstle T, Steiner HH, Herold-Mende C, Gerhards R, Hagmüller E, Steiner HH. Immunization with virus-modified tumor cells. Semin Oncol. 1998 Dec;25(6):677–696. [PubMed]
  • Seong BL, Brownlee GG. A new method for reconstituting influenza polymerase and RNA in vitro: a study of the promoter elements for cRNA and vRNA synthesis in vitro and viral rescue in vivo. Virology. 1992 Jan;186(1):247–260. [PubMed]
  • Talon J, Horvath CM, Polley R, Basler CF, Muster T, Palese P, García-Sastre A. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol. 2000 Sep;74(17):7989–7996. [PMC free article] [PubMed]
  • Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, Muster T, García-Sastre A, Palese P. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4309–4314. [PubMed]
  • Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, Wittes J, Bryant M. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine. 1999 Dec 10;18(9-10):899–906. [PubMed]
  • van den Broek MF, Müller U, Huang S, Aguet M, Zinkernagel RM. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol. 1995 Aug;69(8):4792–4796. [PMC free article] [PubMed]
  • Wang X, Li M, Zheng H, Muster T, Palese P, Beg AA, García-Sastre A. Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol. 2000 Dec;74(24):11566–11573. [PMC free article] [PubMed]

Articles from Philosophical Transactions of the Royal Society B: Biological Sciences are provided here courtesy of The Royal Society